Assert-IQ vs Cleerly LABS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Abbott Medical
VS
by Cleerly

AI Verdict

Assert-IQ focuses on long-term, continuous monitoring of cardiac rhythms to detect arrhythmias using an insertable device. In contrast, Cleerly LABS utilizes AI to analyze coronary CT angiography (CCTA) images for the detection and characterization of atherosclerosis and stenosis. While both tools contribute to cardiovascular disease management, they address distinct diagnostic needs related to heart electrical activity versus structural arterial health.

Choose Assert-IQ if…

Choose Assert-IQ if your primary goal is long-term, continuous monitoring to diagnose elusive or infrequent cardiac arrhythmias. This tool is ideal for patients experiencing intermittent symptoms such as syncope, palpitations, or cryptogenic stroke where a suspected heart rhythm disorder requires prolonged observation beyond standard external monitors. It provides comprehensive arrhythmia detection over several years, enabling timely diagnosis and management.

View Assert-IQ →

Choose Cleerly LABS if…

Choose Cleerly LABS if you need a detailed, AI-powered assessment of coronary artery disease based on CT angiography. This software is best suited for evaluating the presence, extent, and characteristics of atherosclerosis and stenosis in patients with known or suspected CAD. It provides critical insights for personalized risk assessment, guiding treatment strategies, and tracking disease progression over time.

View Cleerly LABS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Assert-IQ Cleerly LABS
Pricing Enterprise Per analysis
Deployment Hybrid Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer.
FDA Status Cleared AI-estimated 1 AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cleerly LABS

Cleerly LABS offers a web-based application with 3D visualization and explicit integration with PACS, RIS, and EHR systems, providing a direct and interactive experience for clinicians analyzing imaging data. Assert-IQ, while offering remote monitoring and a patient app, primarily functions as a device-plus-platform, and the clinician interface for its cloud platform is not as explicitly detailed for interactive analysis.

Clinical Value

Cleerly LABS

Cleerly LABS provides a novel, AI-powered approach to cardiovascular disease management by offering comprehensive, quantitative analysis of coronary plaque beyond traditional stenosis, aiming to personalize heart attack prevention. Assert-IQ offers crucial long-term continuous cardiac monitoring for arrhythmia detection, which is an advancement in its field, but Cleerly's focus on detailed plaque characterization addresses a broader and potentially more impactful area of cardiovascular disease prevention.

Pricing & Value

Cleerly LABS

Cleerly LABS provides transparent per-analysis pricing, including retail and discounted rates, and mentions potential insurance coverage, allowing for clear cost assessment. Assert-IQ's pricing is opaque, listed as 'enterprise' and requiring direct contact with Abbott Medical for institutional pricing, which makes it difficult for potential customers to evaluate its value proposition upfront.

Enterprise Readiness

Assert-IQ

Abbott Medical, the company behind Assert-IQ, is a global healthcare leader founded in 1888, providing a highly established infrastructure, extensive experience, and a broad network for enterprise-level deployment and support. While Cleerly LABS offers robust cloud-based deployment and integration with PACS/RIS/EHR, Abbott's long-standing history and explicit targeting of large health systems give it a significant advantage in overall enterprise readiness.

Innovation

Cleerly LABS

Cleerly LABS offers a highly innovative, AI-driven solution that fundamentally changes how coronary artery disease is assessed by quantifying and characterizing plaque beyond simple stenosis, with the stated mission to eliminate heart attacks. Assert-IQ, while an advanced insertable cardiac monitor with extended monitoring capabilities and improved data transmission, represents an evolutionary improvement within an existing device category rather than a disruptive new approach.

Support & Docs

Assert-IQ

Abbott Medical, as a large and established global healthcare company, possesses a comprehensive and mature infrastructure for customer support, technical documentation, and professional resources for its products. While Cleerly offers client support and resources, the extensive scale and long-standing presence of Abbott suggest a more robust and readily available support ecosystem for enterprise clients.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Assert-IQ Cleerly LABS
Name Assert-IQ Cleerly LABS
Company Abbott Medical Cleerly
Primary Function Long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management.
Key Feature (Monitoring/Analysis) Long-term continuous cardiac monitoring (up to 6 years) with advanced arrhythmia detection algorithms. AI-powered CCTA image analysis for comprehensive coronary plaque assessment (volume, type) and stenosis detection and quantification.
Target Specialties/Categories Cardiology, Internal Medicine Cardiology AI, Radiology & Imaging AI
Data Export/Integration yes (data export) Integration with PACS, RIS, EHR via Cleerly Proxy

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Cleerly LABS.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Assert-IQ is designed for long-term, continuous monitoring and advanced arrhythmia detection to aid in diagnosing and managing patients with suspected heart rhythm disorders. Cleerly LABS is an AI-powered software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, assisting in personalized heart disease management.
Assert-IQ is an Insertable Cardiac Monitor (ICM) system that provides continuous cardiac monitoring, leveraging Bluetooth Low Energy for data transmission and a secure cloud-based platform. Cleerly LABS is a web-based, AI-powered software that analyzes non-invasive CCTA images to provide detailed assessments of coronary plaque and stenosis.
Assert-IQ offers long-term, continuous cardiac monitoring for up to 6 years, with options for at least three or six years of battery life. Cleerly LABS provides analysis of CCTA scans at a point in time, with features to track disease progression over time through repeat analyses.
Assert-IQ delivers advanced arrhythmia detection algorithms, proactive clinician alerts, and IQ Insights showing trends and timelines for a holistic view of cardiovascular health. Cleerly LABS provides comprehensive coronary plaque assessment (volume, type), stenosis detection and quantification, 3D visualization of coronary arteries, and personalized heart disease risk assessment.
Assert-IQ is offered under an enterprise pricing model, requiring direct contact with Abbott Medical for institutional pricing. Cleerly LABS is priced per analysis, with a retail price of $1500, currently offered at a discounted rate of $750, with the CCTA scan cost being separate and some insurance coverage available.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.